819 related articles for article (PubMed ID: 36536232)
1. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
2. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.
Gao B; Wang Y; Li C; Lu S
Front Immunol; 2023; 14():1114717. PubMed ID: 36814910
[TBL] [Abstract][Full Text] [Related]
3. A novel epithelial-mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma.
Shi Y; Wang J; Huang G; Zhu J; Jian H; Xia G; Wei Q; Li Y; Yu H
Hepatol Int; 2022 Aug; 16(4):906-917. PubMed ID: 35699863
[TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
5. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma.
Chen S; Zhao E
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101587. PubMed ID: 33662631
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of a stemness-based classifier for prognosis and immunotherapy response of hepatocellular carcinoma based on bioinformatics and machine-learning strategies.
Chen E; Zou Z; Wang R; Liu J; Peng Z; Gan Z; Lin Z; Liu J
Front Immunol; 2024; 15():1244392. PubMed ID: 38694506
[TBL] [Abstract][Full Text] [Related]
8. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
9. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
10. Identification of chromatin organization-related gene signature for hepatocellular carcinoma prognosis and predicting immunotherapy response.
Chen J; Chen X; Li T; Wang L; Lin G
Int Immunopharmacol; 2022 Aug; 109():108866. PubMed ID: 35691273
[TBL] [Abstract][Full Text] [Related]
11. Establishing a Prognostic Signature Based on Epithelial-Mesenchymal Transition-Related Genes for Endometrial Cancer Patients.
Liu J; Cui G; Shen S; Gao F; Zhu H; Xu Y
Front Immunol; 2021; 12():805883. PubMed ID: 35095892
[TBL] [Abstract][Full Text] [Related]
12. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
14. Identification of PANoptosis-related subtypes, construction of a prognosis signature, and tumor microenvironment landscape of hepatocellular carcinoma using bioinformatic analysis and experimental verification.
Ouyang G; Li Q; Wei Y; Dai W; Deng H; Liu Y; Li J; Li M; Luo S; Li S; Liang Y; Pan G; Yang J; Gan T
Front Immunol; 2024; 15():1323199. PubMed ID: 38742112
[TBL] [Abstract][Full Text] [Related]
15. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
Front Immunol; 2022; 13():856186. PubMed ID: 35479067
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of tumor mutation burden and immune infiltration in hepatocellular carcinoma based on TCGA data.
Liu S; Tang Q; Huang J; Zhan M; Zhao W; Yang X; Li Y; Qiu L; Zhang F; Lu L; He X
Aging (Albany NY); 2021 Apr; 13(8):11257-11280. PubMed ID: 33820866
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
18. Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma.
Zhou Y; Wang L; Zhang W; Ma J; Zhang Z; Yang M; Yu J; Luo J; Yan Z
Dis Markers; 2022; 2022():6335155. PubMed ID: 35111268
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]